A breast cancer liquid biopsy is a quick and painless substitute for surgical biopsies that enables doctors to learn many details about a tumor from just one blood sample. Cancer DNA traces in the blood can indicate the treatments that a patient is most likely to benefit from.
The market for breast cancer liquid biopsy in 2021 was USD 124.46 million and will reach USD 604.71 million by 2030, growing at a 19.2% CAGR during 2021-2030.
The market for breast cancer liquid biopsies is expanding as a result of rising rates of breast cancer in the population, more knowledge of early detection and treatment, and rising consumer desire for minimally invasive procedures. The WHO predicts that 2.3 million women worldwide will receive a breast cancer diagnosis in 2020, leading to 685,000 deaths. Additionally, liquid biopsies are a revolutionary technique for the early identification of breast cancer, significantly boosting market expansion.
Rising rates of breast cancer are driving the market, rising preferences for minimally invasive procedures, government, and international health organization initiatives, technological advancements to boost market revenues, rising emphasis on personalize medicine in clinical practice, and rising funding for liquid biopsy R&D. A few of the factors propelling the market growth include rising patient awareness of breast cancer treatment, benefits of breast cancer liquid biopsy tests over conventional tests, increase adoption of liquid biopsy tests, an increase in pre-screening programs and next-generation sequencing (NGS) among healthcare professionals, and rising demand for breast cancer liquid biopsy reagent kits.
The development of the market is severely constrain by the lack of accessibility to and awareness of breast cancer in developing nations. Additionally, there is a shortage of qualify doctors, and late-stage diagnosis occurs occasionally.
The market growth for breast cancer liquid biopsy will probably be aided by more regulatory approvals from governmental organizations worldwide. Additionally, liquid biopsy is a clinically useful alternative to traditional methods for detecting breast cancer. According to a survey, patients with identifiable circulating tumor cells in their blood samples have a low risk of developing breast cancer again after receiving a liquid biopsy. All of these elements support several future chances for market expansion.
On the basis of indicators, the market is segment into extracellular vesicles, circulating tumor cells, circulating cell free DNA, and other circulating biomarkers.
In 2021, the sector for circulating cell-free DNA (cfDNA) account for the biggest revenue share. The ability of cfDNA to diagnosis recurrence or progression, detect growing genomic anomalies link to drug resistance, and track tumor molecular profiles in real-time at several periods is credit with the technology’s commercial domination.
During the project period, the sector for circulating tumor cells (CTCs) will develop at the fastest rate. The larger share of this segment is due to the capacity of CTCs to provide increase sensitivity as early cancer detection biomarkers, with larger CTCs counts tied to a very high risk of getting cancer.
On the basis of end users, the market is segment into research institutes, hospitals, physician laboratories, public health laboratories, physician laboratories, small molecular laboratories, reference laboratories, and pathology laboratories.
The reference laboratories segment rule the overall breast cancer liquid biopsy market. A “Reference laboratory,” as define by Medicare, is a lab that receives a sample from another lab and does one or more tests. Physician offices, private practitioners, hospitals, and other healthcare facilities like nursing homes refer patients for the majority of the tests that are carry out.
In 2021, the largest regional market was held by North America. Rapid technological development, the use of liquid biopsies in treatment decision-making, and expanding government initiatives can all be credit for the domination. Due to higher investments and the existence of numerous biotechnology businesses producing the tests, the U.S. dominates the North American market.
Over the forecast period, Asia Pacific will witness profitable growth. The population is expanding, there is a growing need for services, and more businesses are joining the market, all contributing to the expansion. According to Global Cancer Statistics 2020, Asia was home to an estimate 58.3% of cancer deaths and approximately half of all cancer incidences in 2020.
Key Players in the breast cancer liquid biopsy market
- Bio-Rad Laboratories
- Johnson & Johnson (Janssen Diagnostics)
- F. Hoffmann-La Roche Ltd
- Myriad GeneticsJanssen Diagnostics
- Guardant Health Inc.
- Adaptive Biotechnologies
- Epic Sciences
- Fluxion Biosciences Inc.
- Illumina Inc.
The market for breast cancer liquid biopsy in 2021 was USD 124.46 million and will reach USD 604.71 million by 2030, growing at a 19.2% CAGR during 2021-2030. The market growth is due to the rising prevalence of breast cancer in the population and the need to deliver diagnosis solutions sooner than alternative tissue biopsy procedures, allowing doctors to make more inform treatment decisions.